Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Olink specialises in solutions for proteomics discovery and development.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

The Pharma Data

DECEMBER 16, 2020

TWO NOVEL SOLID TUMOUR TARGETS FROM THE PARTNERSHIP TRANSITION INTO DRUG DISCOVERY. This has enabled the generation of a pipeline of novel first-in-class targeted protein degradation projects. Evotec will be responsible for progressing the drug discovery programmes to IND filing.

Protein 40

Protein Containment Bioinformatics Drugs 40

Scienmag

OCTOBER 27, 2020

Scientists from the iMolecule group at Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) developed BiteNet, a machine learning (ML) algorithm that helps find drug binding sites, i.e. potential drug targets, in proteins. BiteNet can analyze 1,000 protein structures in 1.5

Drugs 59

Drugs Protein Engineer Scientist 59

pharmaphorum

AUGUST 10, 2021

Oxford University and UK clinical artificial intelligence (AI) company Sensyne Health will partner on a project to find new drug targets for people with hard-to-treat asthma. Dr Timothy Hinks. According to Hinks, “we still don’t understand the causes of asthma, because in the past the scientific tools just didn’t exist.

Gene Sequencing 116

Gene Sequencing Bioinformatics Gene Genome 116

Scienmag

SEPTEMBER 23, 2020

These molecular insights may foster effective therapies using existing drugs for patients with COVID-19. – Viral and bacterial pathogens wield pathogenic or virulent proteins that interact with high-value targets inside human cells, attacking what is known as the host interactome. Credit: UAB BIRMINGHAM, Ala.

Protein 85

Protein Drugs Bioinformatics Genetics 85

STAT News

MARCH 6, 2023

Unlike most people who receive medications yet to be cleared by the Food and Drug Administration, none of these patients is getting the vaccines as part of a clinical trial. Neoantigen vaccines are designed to target certain proteins called neoantigens on tumor cells. “It really was a choice of this or nothing.”

Vaccination 98

Vaccination Vaccine Drugs Clinical Trials 98

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein 52

Protein Clinical Trials Clinical Trials Antibody 52

Scienmag

MARCH 4, 2021

Researchers at Baylor College of Medicine show that analysis of the proteomics, or all the protein data, from aggressive human cancers is a useful approach to identify potential novel therapeutic targets.

Protein 46

Protein Medicine Drugs Research 46

pharmaphorum

APRIL 1, 2021

AI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Hungary. We speak to the company’s CEO and co-founder, Szabolcs Nagy, to find out why moving beyond traditional biotech drug development is a good fit for the country’s ecosystem. They go into bioinformatics”. So what do they do?

Bioinformatics 103

Bioinformatics Drugs Development Scientist 103

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Big Data 40

Big Data Development Life Science Drugs 40

pharmaphorum

OCTOBER 20, 2021

The system could also have applications in evaluating drugs in clinical trials, helping to gauge if a therapy is having an impact early on in the disease process.

Trials 78

Trials Genome Genomics Bioinformatics 78

XTalks

DECEMBER 13, 2023

This impressive growth can be attributed to Fulgent’s distinctive chemistries and advanced proprietary bioinformatics pipeline, which have been instrumental in fueling the company’s rapid advancement in recent years. This substantial investment is accelerating the growth of their new drug pipeline. million and $38.8 million and $33.9

Genetics 111

Genetics Vaccination Vaccine DNA 111

Drug Discovery World

OCTOBER 7, 2022

To investigate the immune environment that surrounds these chemotherapy-resistant tumours, the researchers employed multiple and novel complementary technologies looking at proteins and genes on both pre-treatment and post-treatment breast cancer tissue.

Research 52

Research Immune Response Gene Bioinformatics 52

Drug Discovery World

NOVEMBER 15, 2022

Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. . It has made its way into almost every aspect of drug discovery, whether it’s exploring basic biology, modelling diseases, identifying and validating targets, or performing drug screens. .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Antibody drug conjugates (ADCs) This session will include three presentations, two clinical updates, two poster highlights, and two luncheon presentations.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Jonathan Fisher, PhD, Group Leader, University College London, on: ‘Local secretion of immune active proteins for direct and bystander tumour killing’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

APRIL 14, 2023

DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick , about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. To do this, Nautilus will useits protein analysis platform to provide TGen with data on the proteins involved in DPIG.

Protein 52

Protein Genome Genomics DNA 52

Drug Discovery World

NOVEMBER 4, 2022

In order to design novel antibodies against specific protein epitopes, it is necessary to generate accurate models of their structure at speed and scale. Bioinformatics 2021 . The post Exscientia extends capabilities beyond small molecules appeared first on Drug Discovery World (DDW). References . Abanades et al.

Antibody 52

Antibody Bioinformatics Engineer Protein 52

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. He holds an MS degree in Statistics and a BS-equivalent in Bioengineering.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

The Pharma Data

SEPTEMBER 1, 2020

Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Presentation Topic: Biomarkers and Bioinformatics. with arrhythmias requiring treatment with Class 1a or III anti-arrhythmic drugs. Author: Minton. Presentation Number: P1133.

Trials 52

Trials Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

JULY 27, 2021

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

Production 52

Production Antibody Sales Manufacturing 52

Drug Discovery World

APRIL 14, 2023

He is being recognised for illuminating research contributions to defining the links between chromosomal abnormalities and cancer, including his discovery of TMPRSS2-ETS gene fusions in prostate cancer, and for pioneering the use of pathological and bioinformatic methodologies to diagnose and track prostate cancer onset and progression.

Genetics 52

Genetics Research Medicine Clinical Research 52

Drug Discovery World

JULY 29, 2022

Scientists from seven research institutions including the University of Oxford and the University of Edinburgh have used pioneering bioinformatic modelling to investigate the molecular interactions of the p53 protein known to give protection against cancers. appeared first on Drug Discovery World (DDW).

Gene 52

Gene DNA Protein Genetics 52

pharmaphorum

SEPTEMBER 14, 2020

While there may be just under 20,000 confirmed protein coding genes, it turns out that much of the genome outside of these genes is also important in regulating how the genome is controlled. On one hand, unfortunately this means that many drugs are doomed to failure. Now, however, the field is changing with respect to genomic medicine.

Genome 116

Genome Genomics Medicine Gene 116

Drug Discovery World

SEPTEMBER 7, 2022

This paid-for advertorial by Benchling appeared in the DDW ebook – AI in drug discovery: How technology is driving innovation. From discovery, to lead optimsation, process development, pre-clinical, and even investigational new drug filings, each stage of R&D stands to benefit from AI. . …on a flexible software platform .

Scientist 52

Scientist Life Science Antibody Protein 52

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genome 52

Genome Genomics RNA Genome Project 52

XTalks

NOVEMBER 7, 2022

Immunofluorescent staining of CTCs is a CTC isolation method that has been used since the first US Food and Drug Administration (FDA) approval in 2013 for the CellSearch ® CTC enumeration platform. Optimal methods for bioinformatic analysis are still needed. percent show less reliability). Exosome-Based Liquid Biopsy in Oncology.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

APRIL 21, 2023

Atrandi Biosciences’ novel technology platform enables researchers to gain insights into the biology of single cells, offering immediate applications in single-cell sequencing, drug and antibody discovery, functional metagenomics, microbial analysis, directed evolution, and synthetic biology. It will be led by Björn C.

Doctors 52

Doctors Doctor Genetics In-Vitro 52

pharmaphorum

MARCH 28, 2022

AION Labs’ third call for applications seeks computational biologists, bioinformatics and cheminformatics scientists, AI researchers, and antibody or protein engineers at academic and industry research labs worldwide to assemble a fully funded start-up company.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. They tell you, ‘that’s a drug that saves us from the coronavirus.’

Vaccination 52

Vaccination Vaccine Regulation Drugs 52